{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:22:38Z","timestamp":1775816558657,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jacl.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:52:14Z","timestamp":1571683934000},"page":"970-978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin\/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations"],"prefix":"10.1016","volume":"13","author":[{"given":"Paul N.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Krempf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bruckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Thomas","family":"DiCioccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.10.007_bib1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2019.10.007_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.10.007_bib3","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.10.007_bib4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","article-title":"Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody","volume":"8","author":"Hopkins","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2019.10.007_bib5","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jacl.2019.10.007_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jacl.2016.09.009","article-title":"Familial defective apolipoprotein B-100: a review","volume":"10","author":"Andersen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.007_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000179","article-title":"Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives","volume":"26","author":"Sjouke","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.007_bib8","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1074\/jbc.M008890200","article-title":"The molecular mechanism for the genetic disorder familial defective apolipoprotein B100","volume":"276","author":"Bor\u00e9n","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2019.10.007_bib9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2019.10.007_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: a key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"issue":"Suppl","key":"10.1016\/j.jacl.2019.10.007_bib11","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2019.10.007_bib12","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.10.007_bib13","first-page":"e201702","article-title":"The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol","volume":"2017","author":"Seidah","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.jacl.2019.10.007_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/fca.13.107","article-title":"Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody","volume":"10","author":"Roth","year":"2014","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacl.2019.10.007_bib15","doi-asserted-by":"crossref","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"Rey","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.10.007_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.10.007_bib17","first-page":"493","article-title":"New developments in atherosclerosis: clinical potential of PCSK9 inhibition","volume":"11","author":"Giunzioni","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jacl.2019.10.007_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00395-017-0619-0","article-title":"Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease","volume":"112","author":"Glerup","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacl.2019.10.007_bib19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2019.10.007_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2019.10.007_bib21","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jacl.2017.08.016","article-title":"Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia","volume":"11","author":"Defesche","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.007_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2019.10.007_bib23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacl.2017.12.008","article-title":"Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia","volume":"12","author":"Hartgers","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.10.007_bib24","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.10.007_bib25","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2019.10.007_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1146\/annurev-biochem-062917-011852","article-title":"Retrospective on cholesterol homeostasis: the central role of Scap","volume":"87","author":"Brown","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jacl.2019.10.007_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.10.007_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.86.2.587","article-title":"Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100","volume":"86","author":"Soria","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2019.10.007_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","article-title":"PCSK9 and lipid lowering drugs","volume":"437","author":"Guo","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacl.2019.10.007_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2019.10.007_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jacl.2019.10.007_bib32","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.10.007_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of alirocumab on lipoprotein(a) over >\/=1.5 years (from the Phase 3 ODYSSEY program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:56Z","timestamp":1761831296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419302910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1933287419302910"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.10.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin\/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}